Specific inhibition of bile acid transport alters plasma lipids and GLP-1
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elobixibat is a minimally absorbed ileal bile acid (BA) transporter (IBAT) inhibitor in development against chronic constipation (CC) and constipation-predominant Irritable Bowel Syndrome (IBS-C). CC is associated with an increased risk for cardiovascular disease and type2 diabetes mellitus. The objectives of this study were to evaluate metabolic effects of elobixibat. Effects on plasma lipids and BA synthesis were evaluated utilizing a 4-week, placebo-controlled study in patients with dyslipidemia while changes of glucagon-like peptide-1 (GLP-1) by elobixibat was assayed in samples from a 14 day high-dose elobixibat study in patients with CC. METHODS: Thirty-six dyslipidemic patients, 21 females, mean age 63 years, were randomized to 2.5 mg or 5 mg elobixibat or placebo once daily for four weeks. The primary endpoint was the change in low density lipoprotein (LDL) cholesterol. Secondary endpoints included other lipid parameters and serum 7α-hydroxy-4-cholesten-3-one (C4), a marker of BA (bile acid) synthesis. Another study, in 36 patients with CC treated with high dose elobixibat; 15 mg or 20 mg/day or placebo for 14 days, was evaluated for changes in GLP-1. RESULTS: In the dyslipidemia study LDL cholesterol was reduced by 7.4 % (p = 0.044), and the LDL/HDL ratio was decreased by 18 % (p = 0.004). Serum C4 increased, indicating that BA synthesis was induced. No serious adverse events were recorded. In the CC study, GLP-1 increased significantly in both the 15 mg (20.7 ± 2.4 pmol/L; p = 0.03) and the 20 mg group (25.6 ± 4.9 pmol/L; p = 0.02). CONCLUSIONS: Elobixibat reduces LDL cholesterol and LDL/HDL ratio and increase circulating peak GLP-1 levels, the latter in line with increased intestinal BA mediated responses in humans. TRIAL REGISTRATIONS: ClinicalTrial.gov: NCT01069783 and NCT01038687 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885 · cited 2×
“inhibition stimulates intestinal L cells, presumably through elevated BAs in the intestine interacting with TGR5 receptors, thereby stimulating synthesis and secretion of GLP-1 [6, 7, 9, 26, 27].”
BackgroundA catalogue of reporting guidelines for health research
Simera, I., Moher, D., Hoey, J., Schulz, K. F., & Altman, D. G. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02234.x · Cited by 1,047 · cited 1×
“Reporting of the studies conform to CONSORT-revised and the EQUATOR guidelines [17].”
MethodKatsuma, S., Hirasawa, A., & Tsujimoto, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.139 · Cited by 789 · cited 2×
“How BAs modulate glucose homeostasis has lately gained renewed interest with studies claiming increased release of glucagon-like peptide-1 (GLP-1) from the intestine following administration with a bile acid binding sequestrant [9] and after rectal administration of taurocholate [10].”
BackgroundStatins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., et al. (2007) · JAMA · doi:10.1001/jama.297.5.499 · Cited by 724
Bytzer, P., Talley, N. J., Leemon, M., Young, L. J., Jones, M. P., & Horowitz, M. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.16.1989 · Cited by 632 · cited 1×
“The positive effects of IBAT-inhibition on GLP-1 secretion may thus be particularly beneficial in CC patients with T2DM or pre-diabetes; two disease entities associated with increased risk for constipation [18, 32, 33].”
BackgroundColonic Secretion of Water and Electrolytes Induced by Bile Acids: Perfusion Studies in Man
Mekhjian, H. S., Phillips, S. F., & Hofmann, A. F. (1971) · Journal of Clinical Investigation · doi:10.1172/jci106644 · Cited by 584 · cited 1×
“Inhibition of IBAT reduces the active ileal absorption of BAs, increasing the content of BAs in the colon, thereby stimulating colonic secretion and motility [1, 2].”
BackgroundThe proximal colonic motor response to rectal mechanical and chemical stimulation
Bampton, P. A., Dinning, P. G., Kennedy, M. L., Lubowski, D. Z., & Cook, I. J. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00194.2001 · Cited by 215 · cited 1×
“Inhibition of IBAT reduces the active ileal absorption of BAs, increasing the content of BAs in the colon, thereby stimulating colonic secretion and motility [1, 2].”
BackgroundThe bile acid membrane receptor TGR5: a valuable metabolic target
Pols, T. W. H., Noriega, L. G., Nomura, M., Auwerx, J., & Schoonjans, K. (2011) · Digestive Diseases · doi:10.1159/000324126 · Cited by 185 · cited 3×
“Thus, BAs regulate glucose and lipid metabolism as well as energy expenditure [6].”
BackgroundWong, B. S., Camilleri, M., McKinzie, S., Burton, D., Graffner, H., & Zinsmeister, A. R. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.285 · Cited by 133 · cited 3×
“Efficacy on pharmacodynamics and clinical endpoints of CC and safety assessments have been reported previously [5].”
BackgroundSimrén, M., Bajor, A., Gillberg, P.-G., Rudling, M., & Abrahamsson, H. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04675.x · Cited by 114 · cited 1×
“1–10 mg), administration of elobixibat was found to be safe and tolerable across the dose levels tested with no serious adverse events or discontinuations [4] and in two Phase II studies in patients with CC, dose levels of 5–10–15–20 mg have been evaluated with beneficial effects on stool frequency, stool consistency…”
Background
Cited by
Bile acids in glucose metabolism and insulin signalling — mechanisms and research needs
Ahmad, T. R., & Haeusler, R. A. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0266-7 · Cited by 337
Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease
Hegyi, P., Maléth, J., Walters, J. R., Hofmann, A. F., & Keely, S. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00054.2017 · Cited by 269
Nakajima, A., Seki, M., Taniguchi, S., Ohta, A., Gillberg, P.-G., Mattsson, J. P., & Camilleri, M. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30123-7 · Cited by 169
Self-citationNewsome, P. N., Palmer, M., Freilich, B., Sheikh, M. Y., Sheikh, A., Sarles, H., Herring, R., Mantry, P., Kayali, Z., Hassanein, T., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.024 · Cited by 80
New Insights Into the Anti-Diabetic Actions of Metformin: From the Liver to the Gut
Wu, T., Horowitz, M., & Rayner, C. K. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1273769 · Cited by 64
“The resulting increase in fecal bile acid excretion enhances bile acid synthesis from cholesterol, which is likely to account for metformin-induced lowering of serum cholesterol concentrations [56,57].”
Background
Metadata
- Authors
- Rudling, M., Camilleri, M., Graffner, H., Holst, J. J., & Rikner, L.
- Venue
- BMC Cardiovascular Disorders
- Published
- 2015-07-22
- Volume
- 15
- Issue
- 1
- Pages
- 75-75
- ISSN
- 1471-2261 (ISSN-L)
- OpenAlex
- W1901029932
- Cited by
- 60
- References
- 12
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Specific inhibition of bile acid transport alters plasma lipids and GLP-1. https://app.cochat.ai/papers/10.1186/s12872-015-0070-9
- The paper
- Rudling, M., Camilleri, M., Graffner, H., Holst, J. J., & Rikner, L. (2015). Specific inhibition of bile acid transport alters plasma lipids and GLP-1. BMC Cardiovascular Disorders. https://doi.org/10.1186/s12872-015-0070-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.